key: cord-0967821-8etjhw9v
authors: Srivastava, Smriti; Singh, Parul; Malhotra, Rajesh; Mathur, Purva
title: False-Positive Human Immunodeficiency Virus Reactivity in COVID Patients: A Word of Caution
date: 2022-02-28
journal: J Glob Infect Dis
DOI: 10.4103/jgid.jgid_226_21
sha: 68b9e45a95aec3c995b6cdb0be7c9fdd44a8d34a
doc_id: 967821
cord_uid: 8etjhw9v

nan

In the first case, a 69-year-old male was admitted with COVID-19 associated respiratory distress on April 16, 2021. The patient developed COVID ARDS, sepsis, and acute kidney injury. He succumbed to cardiac arrest on day 23. Viral markers for HIV, HBsAg, and HCV were requested on day 14.

We noted that TRI-DOT was nonreactive, whereas VIDAS was reactive with 2.48 s/CO ratio for anti-HIV ½, antigen (p24) was not detected by VIDAS (A signal/cutoff ratio of ≥0.25 is considered reactive). He tested nonreactive for HBsAg (VIDAS®) and HCV (HCV TRI-DOT). COVID antibodies using VIDAS® severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) IgG and IgM were found 0.87 (s/CO) for IgM and 15.50 for IgG. (s/CO values of ≥1 are considered reactive).

A repeat sample on day 17 gave similar results. (TRI-DOT being nonreactive and VIDAS being reactive with 2.91 s/CO ratio for anti-HIV ½). Part of the sample was tested on Abbott Architect platform (Abbott Laboratories, Abbott Park, Illinois, USA) and found reactive with 1.2 s/CO ratio (s/CO values of ≥1 are considered reactive).

The second case was a 9-year-old boy admitted on May 7, 2021, with seizure, and dehydration and diagnosed with COVID by reverse transcription-polymerase chain reaction. Viral markers for HIV, HBsAg, and HCV were requested on day 12 of admission.

We found TRI-DOT nonreactive and VIDAS reactive with 1.22 s/CO ratio for anti-HIV ½. However, antigen (p24) was again not detected. He tested nonreactive for HBsAg (VIDAS®) and HCV (HCV TRI-DOT).

With repeat sample on day 14, TRI-DOT gave a nonreactive result, and VIDAS® HIV was reactive with a s/CO ratio of 0.89. Part of the sample tested on Abbott Architect platform was found nonreactive. COVID antibodies detected by VIDAS® SARS COV-2 IgG and IgM were 0.27 (s/CO) for IgM and 7.20 for IgG.

The clinical and laboratory parameters of both patients are given in Table 1 .

Conclusively, low titers of antibodies are expected in recent HIV infection, very advanced disease, and presence of broadly cross-reacting antibodies. Advanced disease was ruled out on the basis of presenting illnesses, whereas in early HIV infection, the presence of antigen is expected. This leaves us with the cross-reacting antibodies. False-positive reactions with other 4 th generation assays have been seen with schistosomiasis, Epstein-Barr virus, and malignancy. [1] [2] [3] During the current pandemic, Tan et al. also reported two COVID patients who had falsely tested reactive to HIV, on Abbott Architect, whereas VIDAS® HIV and MP Biomedicals HIV immunoblot were negative. [4] The coronavirus spike proteins and envelope glycoproteins of HIV are structurally homologous, extensively glycosylated class 1 type fusion proteins, [5] and some incidents of cross reactivity are expected with an ongoing pandemic. 

Association of schistosomiasis with false-positive HIV test results in an African adolescent population

High positive HIV serology results can still be false positive

Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests

Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results

Common features of enveloped viruses and implications for immunogen design for next-generation vaccines